AI reads heart signals to keep breast cancer treatment safer
NCT ID NCT05623397
First seen Jan 05, 2026 · Last updated May 09, 2026 · Updated 23 times
Summary
This study tested whether an artificial intelligence (AI) model can accurately measure heart rhythm changes in breast cancer patients taking the drug ribociclib. The AI analyzed ECG data from 70 women and was compared to the standard method of measuring heart electrical activity. The goal was to see if the AI could reliably detect any heart-related side effects, potentially making monitoring easier and more accessible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC - Hôpitaux Universitaires Pitié Salpêtrière, Paris, FRANCE
Paris, PARIS, 75651, France
-
Groupe Ambroise Paré, Hartmann
Neuilly-sur-Seine, 92200, France
-
Hôpital Tenon
Paris, 75020, France
-
Institut Gustave Roussy
Villejuif, 94805, France
Conditions
Explore the condition pages connected to this study.